Ascendis Pharma A/S Adjustments For Decrease Increase In Trade And Other Receivables
Ascendis Pharma A/S (ASND) reported Adjustments For Decrease Increase In Trade And Other Receivables of EUR 15.59 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Notes › Receivables
ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables · last filed 2026-02-11
- Ascendis Pharma A/S adjustments for decrease increase in trade and other receivables for the quarter ending 2025-12-31 was -9.55M EUR.
- Ascendis Pharma A/S adjustments for decrease increase in trade and other receivables for the quarter ending 2025-09-30 was -24.91M EUR, a 186.08% decline year-over-year.
- Ascendis Pharma A/S adjustments for decrease increase in trade and other receivables for the quarter ending 2025-06-30 was -47.98M EUR.
- Ascendis Pharma A/S adjustments for decrease increase in trade and other receivables for the quarter ending 2025-03-31 was 98.03M EUR.
| Period end | Adjustments For Decrease Increase In Trade And Other Receivables 3 month | Adjustments For Decrease Increase In Trade And Other Receivables 6 month | Adjustments For Decrease Increase In Trade And Other Receivables 9 month | Adjustments For Decrease Increase In Trade And Other Receivables 12 month |
|---|---|---|---|---|
| 2025-12-31 | -9.55M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | -34.46M EUR derived: sum of 2 quarters · filed 2026-02-11 | -82.44M EUR derived: sum of 3 quarters · filed 2026-02-11 | 15.59M EUR 20-F · filed 2026-02-11 |
| 2025-09-30 | -24.91M EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | -72.89M EUR derived: sum of 2 quarters · filed 2025-11-12 | 25.14M EUR 6-K · filed 2025-11-12 | -99.66M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | -47.98M EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-08-07 | 50.05M EUR 6-K · filed 2025-08-07 | -74.75M EUR derived: sum of 3 quarters · filed 2026-02-11 | -45.81M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | 98.03M EUR 6-K · filed 2025-05-01 | -26.77M EUR derived: sum of 2 quarters · filed 2026-02-11 | 2.17M EUR derived: sum of 3 quarters · filed 2026-02-11 | -9.29M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | -124.80M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | -95.86M EUR derived: sum of 2 quarters · filed 2026-02-11 | -107.32M EUR derived: sum of 3 quarters · filed 2026-02-11 | -118.61M EUR 20-F · filed 2026-02-11 |
| 2024-09-30 | 28.94M EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | 17.48M EUR derived: sum of 2 quarters · filed 2025-11-12 | 6.19M EUR 6-K · filed 2025-11-12 | -2.33M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | -11.46M EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-08-07 | -22.75M EUR 6-K · filed 2025-08-07 | -31.27M EUR derived: sum of 3 quarters · filed 2026-02-11 | -44.80M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -11.29M EUR 6-K · filed 2025-05-01 | -19.81M EUR derived: sum of 2 quarters · filed 2026-02-11 | -33.34M EUR derived: sum of 3 quarters · filed 2026-02-11 | -34.45M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -8.52M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | -22.06M EUR derived: sum of 2 quarters · filed 2026-02-11 | -23.16M EUR derived: sum of 3 quarters · filed 2026-02-11 | -32.77M EUR 20-F · filed 2026-02-11 |
| 2023-09-30 | -13.54M EUR derived: 6-K 9 month − 6-K 6 month · filed 2024-11-14 | -14.64M EUR derived: sum of 2 quarters · filed 2024-11-14 | -24.25M EUR 6-K · filed 2024-11-14 | -29.71M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | -1.11M EUR derived: 6-K 6 month − 6-K 3 month · filed 2024-09-03 | -10.71M EUR 6-K · filed 2024-09-03 | -16.17M EUR derived: sum of 3 quarters · filed 2025-02-12 | -16.55M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -9.61M EUR 6-K · filed 2024-05-02 | -15.06M EUR derived: sum of 2 quarters · filed 2025-02-12 | -15.44M EUR derived: sum of 3 quarters · filed 2025-02-12 | -18.73M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -5.46M EUR derived: 20-F 12 month − 6-K 9 month · filed 2025-02-12 | -5.83M EUR derived: sum of 2 quarters · filed 2025-02-12 | -9.12M EUR derived: sum of 3 quarters · filed 2025-02-12 | -11.53M EUR 20-F · filed 2025-02-12 |
| 2022-09-30 | -376.00K EUR derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | -3.67M EUR derived: sum of 2 quarters · filed 2023-11-07 | -6.07M EUR 6-K · filed 2023-11-07 | -3.44M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | -3.29M EUR derived: 6-K 6 month − 6-K 3 month · filed 2023-09-05 | -5.70M EUR 6-K · filed 2023-09-05 | -3.06M EUR derived: sum of 3 quarters · filed 2024-02-07 | -8.32M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | -2.41M EUR 6-K · filed 2023-04-27 | 229.00K EUR derived: sum of 2 quarters · filed 2024-02-07 | -5.03M EUR derived: sum of 3 quarters · filed 2024-02-07 | -9.18M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | 2.64M EUR derived: 20-F 12 month − 6-K 9 month · filed 2024-02-07 | -2.62M EUR derived: sum of 2 quarters · filed 2024-02-07 | -6.77M EUR derived: sum of 3 quarters · filed 2024-02-07 | -6.66M EUR 20-F · filed 2024-02-07 |
| 2021-09-30 | -5.26M EUR derived: 6-K 9 month − 6-K 6 month · filed 2022-11-02 | -9.40M EUR derived: sum of 2 quarters · filed 2022-11-02 | -9.29M EUR 6-K · filed 2022-11-02 | |
| 2021-06-30 | -4.14M EUR derived: 6-K 6 month − 6-K 3 month · filed 2022-08-10 | -4.04M EUR 6-K · filed 2022-08-10 | ||
| 2021-03-31 | 110.00K EUR 6-K · filed 2022-05-11 | |||
| 2020-12-31 | -2.00M EUR 20-F · filed 2023-02-16 | |||
| 2019-12-31 | -2.18M EUR 20-F · filed 2022-03-02 |